TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2017 Financial Results and Business Update Investor conference call to be held today, Thursday

TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2017

Financial Results and Business Update

Investor conference call to be held today, Thursday March 8, 2018

York, NY, (March 8, 2018)

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its

financial results for the fourth quarter and year ended December

31, 2017 and provided recent company developments along with a

business outlook for 2018.

S. Weiss, the Company's Executive Chairman and Chief Executive

Officer, stated, 2017 was a truly pivotal year for our

company with the presentation of positive results from our first

Phase 3 trial, the GENUINE trial, the completion of enrollment in

our second Phase 3 trial, the UNITY-CLL trial, and the launch of

our Phase 3 ULTIMATE trials in Multiple Sclerosis. These major

milestones along with strong enrollment in our UNITY-NHL

registration directed program sets the stage for an even more

impactful 2018 and 2019. Mr. Weiss continued, We are

extremely pleased to enter 2018 with a healthy balance sheet and

look forward to multiple value creating milestones this year,

including presenting topline ORR data from our Phase 3 UNITY-CLL

trial and, ideally, filing our first BLA and/or NDA later in the

Orphan Drug Designation:

Orphan drug designation was granted

for the combination of ublituximab (TG-1101) and umbralisib

(TGR-1202) for the treatment of Chronic Lymphocytic Leukemia (CLL)

and Diffuse Large B-Cell Lymphoma (DLBCL).

Ublituximab Publication:

Data from the Phase 1/2 trial of

ublituximab was published in the British Journal of

GENUINE Phase 3 Data:

Positive data from the Phase 3 GENUINE

trial of ublituximab in combination with ibrutinib in patients with

high risk CLL was presented at the ASCO annual meeting and Lugano

Lymphoma Conference.

ULTIMATE Phase 3 Trials in MS: Received

a Special Protocol Assessment (SPA) for the Phase 3 ULTIMATE I and

II studies in relapsing forms of multiple sclerosis, commenced

enrollment into the global studies and presented clinical and MRI

data from the supportive Phase 2 trial of ublituximab in RMS at

various conferences throughout the year.

UNITY-CLL Phase 3 Enrollment: Full

enrollment in the UNITY-CLL Phase 3 Trial was completed in October

Umbralisib Grant: Umbralisib was

selected for a grant by the National Multiple Sclerosis Society to

support the development of umbralisib as an oral B-Cell targeted

treatment option in progressive Multiple Sclerosis

Anti-PD-L1 Entered the Clinic: The

Company advanced its anti-PD-L1 monoclonal antibody into clinical

development, with the first patient being dosed in a Phase I

Key Objectives for 2018

UNITY-CLL Phase 3 Trial: We plan to

present top-line overall response rate results from our UNITY-CLL

Phase 3 trial in both front line and relapsed or refractory CLL and

also prepare a BLA/NDA filing for accelerated

GENUINE Phase 3 BLA Filing: A Biologics Licensing Application (BLA)

filing will be prepared for ublituximab plus ibrutinib for

potential accelerated approval based on the results from

UNITY-NHL: Aggressively enroll into all

cohorts of the UNITY-NHL clinical trial with the goal of completing

enrollment into all cohorts.

ULTIMATE Phase 3 Trials: Aggressively

recruit to our Phase 3 MS trials.

Data Presentations: Present new and

updated data from ongoing trials at various scientific meetings

throughout the year.

Financial Results for the Fourth Quarter and Full Year

Cash, cash equivalents, investment

securities, and interest receivable were $84.8 million as of

December 31, 2017. Pro-forma

cash, cash equivalents, investment securities, and interest

receivable as of December 31, 2017 (excluding our first quarter

2018 operations) are approximately $114.6 million, after giving

effect to $29.8 million of net proceeds from the utilization of the

Company's at-the-market ("ATM") sales facility during the first

Research and development (R&D)

expenses were $26.0 million and $102.5 million for the three and

twelve months ended December 31, 2017, respectively, compared to

$22.3 million and $69.2 million for the three and twelve months

ended December 31, 2016, respectively. Included in research and

development expenses for the three and twelve months ended December

31, 2017, in addition to our other clinical expenses, are $6.1

million and $26.6 million, respectively, of manufacturing and CMC

expenses for Phase 3 clinical trials and potential

commercialization. The increase in R&D expenses for both the

three and twelve months ended December 31, 2017, is primarily due

to the ongoing clinical development programs and related

manufacturing costs for TG-1101 and TGR-1202.

General and administrative (G&A)

expenses were $5.1 million and $16.3 million for the three and

twelve months ended December 31, 2017, respectively, as compared to

$1.8 million and $9.9 million for the three and twelve months ended

December 31, 2016, respectively. The increase in G&A expenses

for the three and twelve months ended December 31, 2017 relates

primarily to non-cash compensation expenses related to

equity incentive expense recognized during 2017.

Net Loss: Net loss was $30.9 million and $118.5 million for

the three and twelve months ended December 31, 2017, respectively,

compared to a net loss of $23.7 million and $78.3 million for the

three and twelve months ended December 31, 2016,

The Company believes its cash, cash